Financials data is unavailable for this security.
View more
Year on year Cytokinetics Inc 's revenues fell -92.04% from 94.59m to 7.53m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 388.96m to a larger loss of 526.24m.
| Gross margin | -- |
|---|---|
| Net profit margin | -17,906.24% |
| Operating margin | -16,297.79% |
| Return on assets | -52.96% |
|---|---|
| Return on equity | -- |
| Return on investment | -57.95% |
More ▼
Cash flow in USDView more
In 2023, Cytokinetics Inc increased its cash reserves by 68.79%, or 46.22m. Cash Flow from Investing totalled 239.25m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 414.33m for operations while cash generated from financing totalled 221.32m.
| Cash flow per share | -5.26 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.118 |
|---|---|
| Tangible book value per share | -0.118 |
More ▼
Balance sheet in USDView more
| Current ratio | 9.28 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | 1.02 |
More ▼
